Announcements Trials
Browse Landscape

Phase

Phase 2 42Phase 3 33Phase 1/2 7Phase NA 4Phase 1 3Phase 4 1Phase 2/3 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 383OTHER 349NIH 46OTHER_GOV 6NETWORK 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 56Gynecologic 30Other solid neoplasm 26Lymphoid 26Other hematologic neoplasm 23Sarcoma 22Thoracic 18Gastrointestinal 17Breast 13Genitourinary 11Head & Neck 6Myeloid 4Endocrine 4Dermatologic 4Plasma cell 3Tumor-Agnostic 2Other neoplasm 2Classical hematology 1

Conditions

Multiple Myeloma 3Neoplasms, Plasma Cell 2Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Myeloproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Neutrophilic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Immunoglobulin Light-chain Amyloidosis 1Hodgkin Disease 1Drug-Related Side Effects and Adverse Reactions 1Congenital Abnormalities 1Burkitt Lymphoma 1

Interventions

pomalidomide 1daratumumab 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1Filgrastim 1Fenretinide 1Dexamethasone 1Cyclophosphamide 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × NETWORK × Plasma cell × Clear all
NCT04667663 2026-04-13

CPD-DARA

Cancer Trials Ireland

Phase 1 Active not recruiting
16 enrolled
Plasma cell

Multiple Myeloma

NCT00052884 2023-06-18

Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation

Eastern Cooperative Oncology Group

Phase 1 Terminated
8 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Neoplasms, Plasma Cell, Drug-Related Side Effects and Adverse Reactions

NCT00104923 2017-07-19

Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer

California Cancer Consortium

Phase 1 Completed
29 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Pdgfra-Associated Chronic Eosinophilic Leukemia, Congenital Abnormalities, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡